NextCure (NXTC) Enterprise Value (2018 - 2026)
NextCure (NXTC) posted quarterly Enterprise Value of -$29.7 million for Q1 2026, up 46.75% year-over-year from -$20.3 million in Q1 2025, and up 28.88% quarter-over-quarter from -$41.8 million in Q4 2025.
NextCure (NXTC) Enterprise Value (2018 - 2026) Analysis & Trends
NextCure's Enterprise Value history runs 9 years deep, the most recent figure standing at -$29.7 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 46.75% year-over-year to -$29.7 million; the TTM figure through Mar 2026 stood at -$29.7 million (up 46.75% YoY), while the FY2025 annual figure was -$41.8 million, up 39.06% from the prior year.
- Enterprise Value for Q1 2026 stood at -$29.7 million, up from -$41.8 million in the prior quarter.
- The five-year high for Enterprise Value was -$10.7 million in Q1 2022, with the low at -$159.9 million in Q4 2022.
- The 5-year median for Enterprise Value is -$68.6 million (2024), against an average of -$73.6 million.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value surged 96.01% in 2022, then plunged 1260.89% in 2023.
- NextCure's Enterprise Value stood at -$159.9 million in 2022, then surged by 32.28% to -$108.3 million in 2023, then jumped by 36.64% to -$68.6 million in 2024, then jumped by 39.06% to -$41.8 million in 2025, then rose by 28.88% to -$29.7 million in 2026.
- Business Quant data shows NXTC's Enterprise Value at -$29.7 million in Q1 2026, -$41.8 million in Q4 2025, and -$29.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | -20.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.09 Mn |
| Mar 31, 2026 | -29.74 Mn |
| Dec 31, 2025 | -41.82 Mn |
| Sep 30, 2025 | -29.11 Mn |
| Jun 30, 2025 | -35.31 Mn |
| Mar 31, 2025 | -55.86 Mn |
| Dec 31, 2024 | -68.62 Mn |
| Sep 30, 2024 | -75.31 Mn |
| Jun 30, 2024 | -86.44 Mn |
| Mar 31, 2024 | -96.00 Mn |
| Dec 31, 2023 | -108.30 Mn |
| Sep 30, 2023 | -118.21 Mn |
| Jun 30, 2023 | -130.62 Mn |
| Mar 31, 2023 | -145.49 Mn |
| Dec 31, 2022 | -159.91 Mn |
| Sep 30, 2022 | -31.09 Mn |
| Jun 30, 2022 | -28.20 Mn |
| Mar 31, 2022 | -10.69 Mn |
| Dec 31, 2021 | -219.59 Mn |
| Sep 30, 2021 | -36.70 Mn |